Compare DDD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | ALLO |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.8M | 252.9M |
| IPO Year | N/A | 2018 |
| Metric | DDD | ALLO |
|---|---|---|
| Price | $1.78 | $1.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $4.75 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 3.4M | 2.6M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | $100.00 |
| P/E Ratio | $17.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.32 | $0.86 |
| 52 Week High | $5.00 | $3.78 |
| Indicator | DDD | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 36.88 | 50.25 |
| Support Level | $1.82 | $1.32 |
| Resistance Level | $1.93 | $1.52 |
| Average True Range (ATR) | 0.12 | 0.10 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 14.34 | 32.65 |
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.